HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hiromi Rakugi Selected Research

esaxerenone

1/2022Effect of esaxerenone on nocturnal blood pressure and natriuretic peptide in different dipping phenotypes.
1/2021Efficacy and safety of esaxerenone (CS-3150), a newly available nonsteroidal mineralocorticoid receptor blocker, in hypertensive patients with primary aldosteronism.
1/2021Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone.
1/2021Effect of the Nonsteroidal Mineralocorticoid Receptor Blocker, Esaxerenone, on Nocturnal Hypertension: A Post Hoc Analysis of the ESAX-HTN Study.
1/2020Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
12/2019Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension.
10/2019Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study.
1/2019Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Hiromi Rakugi Research Topics

Disease

78Hypertension (High Blood Pressure)
05/2022 - 06/2002
32Cardiovascular Diseases (Cardiovascular Disease)
11/2021 - 12/2004
30Insulin Resistance
01/2021 - 01/2002
29Chronic Renal Insufficiency
04/2022 - 12/2006
29Essential Hypertension
01/2022 - 07/2003
22Inflammation (Inflammations)
01/2021 - 10/2006
20Fibrosis (Cirrhosis)
01/2021 - 07/2007
20Atherosclerosis
01/2021 - 04/2002
18Type 2 Diabetes Mellitus (MODY)
11/2022 - 11/2002
18Stroke (Strokes)
05/2021 - 07/2009
18Proteinuria
06/2015 - 07/2004
17Diabetes Mellitus
11/2022 - 11/2009
13Obesity
01/2021 - 09/2003
11Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2021 - 04/2002
11Dementia (Dementias)
01/2020 - 07/2009
11Alzheimer Disease (Alzheimer's Disease)
01/2020 - 07/2009
10Neoplasms (Cancer)
10/2021 - 10/2012
10Body Weight (Weight, Body)
01/2020 - 06/2005
8Cognitive Dysfunction
04/2022 - 07/2009
8Frailty
01/2021 - 01/2018
8Vascular Remodeling
12/2020 - 02/2004
7Dyslipidemias (Dyslipidemia)
04/2021 - 05/2011
7Hyperaldosteronism (Conn Syndrome)
01/2021 - 01/2012
7Osteoporosis
03/2019 - 05/2009
7Coronary Artery Disease (Coronary Atherosclerosis)
01/2019 - 04/2004
7Vascular Calcification
01/2019 - 05/2009
7Kidney Diseases (Kidney Disease)
01/2016 - 01/2006
7Chronic Kidney Failure (Chronic Renal Failure)
01/2016 - 01/2010
6Diabetic Nephropathies (Diabetic Nephropathy)
01/2022 - 04/2010
6Albuminuria
01/2021 - 04/2010
6Ulcer
01/2020 - 12/2011
6Peripheral Arterial Disease
08/2018 - 08/2005
6Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
04/2013 - 12/2004
5Sarcopenia
11/2022 - 01/2018
5COVID-19
09/2022 - 11/2020
5Heart Failure
04/2022 - 04/2006
5Fatty Liver
01/2020 - 01/2009
5Cardiomegaly (Heart Hypertrophy)
01/2019 - 01/2002
5Hypertrophy
04/2015 - 04/2006
5Hyperuricemia
01/2013 - 07/2005
4Muscle Weakness
01/2021 - 10/2018

Drug/Important Bio-Agent (IBA)

29Antihypertensive Agents (Antihypertensives)IBA
04/2022 - 06/2002
20Angiotensin IIIBA
11/2021 - 06/2004
16Insulin (Novolin)FDA Link
11/2022 - 01/2002
16Proteins (Proteins, Gene)FDA Link
04/2022 - 12/2007
16Calcium Channel Blockers (Blockers, Calcium Channel)IBA
10/2020 - 02/2004
13Glucose (Dextrose)FDA LinkGeneric
01/2020 - 01/2009
13CreatinineIBA
10/2019 - 06/2005
13Angiotensin Receptor AntagonistsIBA
01/2018 - 04/2005
11Pharmaceutical PreparationsIBA
10/2021 - 04/2005
10SaltsIBA
05/2022 - 07/2003
10Biomarkers (Surrogate Marker)IBA
01/2022 - 07/2009
10olmesartanIBA
01/2022 - 02/2004
10Peptides (Polypeptides)IBA
01/2021 - 06/2011
10AdiponectinIBA
01/2021 - 09/2003
10DiureticsIBA
10/2020 - 06/2005
10benidipineIBA
01/2020 - 09/2007
9AngiotensinsIBA
11/2020 - 01/2002
9Amlodipine (Norvasc)FDA LinkGeneric
01/2018 - 01/2006
8esaxerenoneIBA
01/2022 - 01/2019
8Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA
01/2022 - 01/2019
8Hepatocyte Growth Factor (Growth Factor, Hepatocyte)IBA
01/2020 - 04/2004
8LipidsIBA
01/2019 - 09/2009
8Norepinephrine (Noradrenaline)FDA LinkGeneric
01/2012 - 06/2005
7Uric Acid (Urate)IBA
01/2021 - 07/2005
7MagnesiumIBA
01/2019 - 05/2009
7Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
01/2019 - 01/2006
7CalciumIBA
01/2015 - 04/2005
6VaccinesIBA
09/2022 - 01/2013
6LigandsIBA
01/2021 - 06/2013
6ThiazidesIBA
01/2020 - 04/2012
6Valsartan (Vals)FDA Link
01/2019 - 07/2004
6ReninIBA
01/2019 - 01/2002
6azilsartanIBA
01/2018 - 05/2012
6Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA
01/2018 - 04/2005
6Indicators and Reagents (Reagents)IBA
01/2017 - 10/2011
6Parathyroid Hormone (Parathormone)IBA
11/2016 - 06/2012
6Fibroblast Growth Factor-23IBA
01/2016 - 04/2009
6MineralsIBA
01/2016 - 05/2009
6Losartan (Cozaar)FDA LinkGeneric
05/2015 - 07/2004
6Vitamin DFDA LinkGeneric
01/2015 - 08/2009
6Amyloid beta-PeptidesIBA
01/2012 - 07/2009
5angiotensin I (1-7)IBA
11/2020 - 04/2009
5Hydrochlorothiazide (Esidrix)FDA LinkGeneric
01/2018 - 01/2014
5Phosphates (Orthophosphate)IBA
10/2015 - 05/2009
5Type 1 Angiotensin ReceptorIBA
08/2015 - 07/2004
5candesartanIBA
06/2014 - 12/2007
5Adrenergic Receptors (Adrenergic Receptor)IBA
05/2011 - 07/2005
4Brain Natriuretic Peptide (Natrecor)FDA Link
01/2022 - 01/2010
4sacubitril and valsartan sodium hydrate drug combinationIBA
01/2022 - 11/2017
4Neutralizing AntibodiesIBA
10/2021 - 12/2010
4Angiotensin Receptors (Angiotensin II Receptor)IBA
10/2021 - 07/2007
4Interleukin-6 (Interleukin 6)IBA
01/2021 - 09/2009
4Angiotensin-Converting Enzyme 2IBA
01/2021 - 01/2013
4Messenger RNA (mRNA)IBA
01/2021 - 07/2007

Therapy/Procedure

48Therapeutics
11/2022 - 06/2002
9Renal Dialysis (Hemodialysis)
12/2018 - 07/2009
5Activities of Daily Living (ADL)
04/2022 - 07/2009
5Adrenalectomy
01/2021 - 10/2018
4Glycemic Control
11/2022 - 11/2019